Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Tuesday, 17 October 2017

PCI Biotech: Employee share option scheme

PCI Biotech Holding    

Published: 16:01 CEST 17-10-2017 /GlobeNewswire /Source: PCI Biotech Holding / : PCIB /ISIN: N00010405640

PCI Biotech: Employee share option scheme

Oslo, 17 October 2017 

In accordance with the authorisation granted by the Annual General Meeting 29 May 2017, the Board of Directors of PCI Biotech Holding ASA has awarded a total of 90,000 share options to key employees.

 

The share options are allotted to the newly hired Chief Medical Officer, Hans Olivecrona. Each share option gives the right to subscribe for or acquire one share per option (after PCI Biotech Holding ASA's choice), at a strike price of NOK 22.35, equal to the volume weighted average share price (VWAP) for the last 5 days of trade prior to the grant date. The options can be exercised with 1/3 of the options after one year, further 1/3 after two years and the last third after three years. The share options are lapsing in Q3 2022.

 

After the allocation, Hans Olivecrona holds a total portfolio of 90,000 unexercised share options and 0 shares.

 

The current authorisation, as of 29 May 2017, allows for allocation of additional 1,040,000 share options to key employees.

 

For more information, please contact:

Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429

 
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.




This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: PCI Biotech Holding ASA, Ullernchausséen 64, Oslo 0379, Norway
If you would like to unsubscribe and stop receiving these e-mails click here.